CTIX Upcoming and Past Milestones, Clinical Trials
Post# of 72440
(Total Views: 5141)
Posted On: 03/17/2017 7:39:53 PM
CTIX Upcoming and Past Milestones, Clinical Trials, Recent Interviews
Upcoming Milestones
Past Milestones
Kevetrin
- Orphan drug designation for ovarian cancer
http://www.cellceutix.com/press-release/2016/...ian-cancer
- Orphan drug designation for pancreatic cancer
http://www.cellceutix.com/press-release/2016/...tic-cancer
- Orphan drug designation for retinoblastoma
http://www.cellceutix.com/press-release/2016/...noblastoma
- Rare pediatric disease designation for K-retinoblastoma
http://www.cellceutix.com/press-release/2016/...noblastoma
- Positive primary endpoint and p21 data (Phase 1)
http://www.cellceutix.com/press-release/2016/...e-patients
Brilacidin
- QIDP designation for B-ABSSSI
http://www.cellceutix.com/press-release/2016/...n-from-fda
- Fast track designation for B-OM
http://www.cellceutix.com/press-release/2016/...-mucositis
- B-ABSSSI positive top-line data (Phase 2b)
http://www.cellceutix.com/press-release/2016/...daptomycin
- MTA extension for prophylactic testing in implanted devices
http://www.cellceutix.com/press-release/2016/...infections
- Formulation stable at room temperature
http://www.cellceutix.com/press-release/2016/...oot-ulcers
- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/A...#corresp-1
Prurisol
- Positive top-line data (Phase 2a)
http://www.cellceutix.com/press-release/2016/...y-endpoint
- Positive primary endpoint (Phase 1)
http://www.cellceutix.com/press-release/2016/...ical-trial
- 505(b)(2) pathway
http://www.cellceutix.com/press-release/2016/...iasis-drug
Clinical Trials
1. P (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=1
2. K-OC (Phase 2a, Recruiting )
https://clinicaltrials.gov/ct2/show/NCT030427...amp;rank=2
3. B-OM (Phase 2, Recruiting )
https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
4. P (Phase 2a, Completed )
https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=4
5. P (Phase 2b, Recruiting )
https://clinicaltrials.gov/ct2/show/NCT029493...amp;rank=5
6. B-ABSSSI (Phase 2b, Completed )
https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=6
7. K (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=7
8. B-UP (Phase 2 POC, Recruiting )
http://www.cellceutix.com/press-release/2016/...-proctitis
Pipeline
Recent Interviews
- 2017 Q1 Conference Call Transcript
http://seekingalpha.com/article/4023682-cellc...transcript
- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-inter...-bertolino
- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cell...-milestone
- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a...-jorgensen
MP Advisors Report
http://www.mpadvisor.com/xyz/Cellceutix_160826.pdf
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OC – ovarian cancer
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product
Upcoming Milestones
Past Milestones
Kevetrin
- Orphan drug designation for ovarian cancer
http://www.cellceutix.com/press-release/2016/...ian-cancer
- Orphan drug designation for pancreatic cancer
http://www.cellceutix.com/press-release/2016/...tic-cancer
- Orphan drug designation for retinoblastoma
http://www.cellceutix.com/press-release/2016/...noblastoma
- Rare pediatric disease designation for K-retinoblastoma
http://www.cellceutix.com/press-release/2016/...noblastoma
- Positive primary endpoint and p21 data (Phase 1)
http://www.cellceutix.com/press-release/2016/...e-patients
Brilacidin
- QIDP designation for B-ABSSSI
http://www.cellceutix.com/press-release/2016/...n-from-fda
- Fast track designation for B-OM
http://www.cellceutix.com/press-release/2016/...-mucositis
- B-ABSSSI positive top-line data (Phase 2b)
http://www.cellceutix.com/press-release/2016/...daptomycin
- MTA extension for prophylactic testing in implanted devices
http://www.cellceutix.com/press-release/2016/...infections
- Formulation stable at room temperature
http://www.cellceutix.com/press-release/2016/...oot-ulcers
- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/A...#corresp-1
Prurisol
- Positive top-line data (Phase 2a)
http://www.cellceutix.com/press-release/2016/...y-endpoint
- Positive primary endpoint (Phase 1)
http://www.cellceutix.com/press-release/2016/...ical-trial
- 505(b)(2) pathway
http://www.cellceutix.com/press-release/2016/...iasis-drug
Clinical Trials
1. P (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=1
2. K-OC (Phase 2a, Recruiting )
https://clinicaltrials.gov/ct2/show/NCT030427...amp;rank=2
3. B-OM (Phase 2, Recruiting )
https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
4. P (Phase 2a, Completed )
https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=4
5. P (Phase 2b, Recruiting )
https://clinicaltrials.gov/ct2/show/NCT029493...amp;rank=5
6. B-ABSSSI (Phase 2b, Completed )
https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=6
7. K (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=7
8. B-UP (Phase 2 POC, Recruiting )
http://www.cellceutix.com/press-release/2016/...-proctitis
Pipeline
Recent Interviews
- 2017 Q1 Conference Call Transcript
http://seekingalpha.com/article/4023682-cellc...transcript
- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-inter...-bertolino
- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cell...-milestone
- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a...-jorgensen
MP Advisors Report
http://www.mpadvisor.com/xyz/Cellceutix_160826.pdf
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OC – ovarian cancer
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product
(5)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼